SEARCH

SEARCH BY CITATION

References

  • 1
    Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 4648.
  • 2
    Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 66976.
  • 3
  • 4
    Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Disc 2004; 3: 7639.
  • 5
    Smith CM. Origin and uses of primum non nocere – above all, do no harm! J Clin Pharmacol 2005; 45: 3717.
  • 6
  • 7
    Holstein A, Plaschke A, Ptak M, Egberts E-H, El-Din J, Brockmoller J & Kirchheiner J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycemia on medication with sulfonylurea hypoglycemic agents. Br J Clin Pharmacol 2005; 60: 1036.
  • 8
    Miura M, Tada H, Furukori-Yasui N, Uno T, Sugawara K, Tateishi T, Sukari T. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. Br J Clin Pharmacol 2005; 60: 618.
  • 9
    Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4 megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995; 28: 32832.
  • 10
    Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 2004; 279: 9497503.
  • 11
    Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, Shirai K, Inoue I. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 2004; 49: 5825.
  • 12
    Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11: 597607.
  • 13
    Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74: 3807.
  • 14
    Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77: 34152.
  • 15
    Wilkinson GR. Drug therapy: drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 221121.
  • 16
    Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug–drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005; 45: 47794.
  • 17
    Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 116.
  • 18
  • 19
    Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 52538.
  • 20
    Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 34955.
  • 21
    Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 25163. Erratum in: Pharmacogenetics 2002; 12: 343.
  • 22
    Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003; 13: 24752.
  • 23
    Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. Br J Clin Pharmacol 2002; 53: 4089.
  • 24
    Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 16908.
  • 25
    Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93: 7005.
  • 26
    D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 6459.
  • 27
    Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 228593.
  • 28
    Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 2004; 57: 48794.
  • 29
    Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy: clinical implications. Am J Pharmacogenomics 2003; 3: 30315.
  • 30
    Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 102730.
  • 31
    Furuta T, Takashima M, Shirai N, Xiao F, Hanai H, Ohashi K, Ishizaki T. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient. Clin Pharmacol Ther 2000; 67: 6849.
  • 32
    Furuta T, Shirai N, Ohashi K, Ishizaki T. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol 2003; 25: 13143.
  • 33
    Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 939.
  • 34
    Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004; 4: 173344.
  • 35
    Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin. Pharmacol. 2004; 58: S86771; discussion S872–4.
  • 36
    Food and Drug Administration. Medical devices: clinical chemistry and clinical toxicology devices; drug metabolism enzyme genotyping system. Fed Regist 2005; 70: 1186587.
  • 37
    Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3: 73948.